Publications
Comparing Access to Orphan Medicinal Products (OMPs) in the United Kingdom and other European countries
1 March 2017
The European Commission’s (EC) Orphan Medicinal Products Regulation intended to incentivise the research, development and marketing of new treatments for rare and chronically disabling or life-threatening…
Comparing the UK EQ-5D-3L and the English EQ-5D-5L Value Sets
1 March 2017
Three EQ-5D value sets (the EQ-5D-3L, crosswalk and EQ-5D-5L) are now available for cost utility analysis in the UK and/or England. The value sets’ characteristics differ,…
What is the Normative Basis for Selecting the Measure of ‘Average’ Preferences for Use in Social Choices?
1 February 2017
The aim of this paper is to consider what normative arguments might exist for advocating the use of any given measure of the average in the…
Exploring the Assessment and Appraisal of Regenerative Medicines and Cell Therapy Products: Is the NICE Approach Fit for Purpose?
1 February 2017
In 2016 the University of York undertook a review exercise to determine whether NICE’s existing methods and processes are appropriate for assessment of regenerative medicines. The…
Delivering an Outcomes-based NHS: Creating the Right Conditions
1 February 2017
This OHE Seminar Briefing summarises a seminar given by Dr Nicholas Hicks, Co-founder and Chief Executive of COBIC (Capitated Outcomes-Based Incentivised Care). Dr Hicks describes COBIC’s…
Policy Options for Formulary Development in Middle-income Countries: Mexico Case Study
1 January 2017
PhRMA commissioned OHE Consulting to explore options and recommend methods that could help middle-income countries efficiently and effectively identify medicines for formulary inclusion. In a previous…
Policy Options for Formulary Development in Middle-income Countries
1 January 2017
PhRMA commissioned OHE Consulting to explore options and recommend methods that could help middle-income countries efficiently and effectively identify medicines for formulary inclusion. This report presents a framework…
The Value of Knowing and Knowing the Value: Improving the Health Technology Assessment of Complementary Diagnostics
5 July 2016
“Complementary diagnostics” are defined as tests using biomarkers for risk assessment, diagnosis, prognosis, monitoring, and guiding therapeutic decisions. This White Paper presents a more comprehensive framework for considering their value contribution.
Important Aspects of Health Not Captured by EQ-5D: Views of the UK General Public
12 January 2016
This Research Paper reports the views of 179 members of the UK general public about important aspects of health that they consider to be missing from the five dimensions of the EQ-5D instrument.